Evaluation of cycloserine dose regimens in an Indian cohort with multidrug-resistant tuberculosis: a population pharmacokinetic analysis.

ABSTRACT: Cycloserine is recommended for inclusion in regimens for multidrug-resistant tuberculosis (MDR-TB). Its efficacy is time dependent and relies on the concentration remaining above the minimum inhibitory concentration (MIC); however, there is a concentration-dependent risk of neurotoxicity. Limited pharmacokinetic (PK) data are available in individuals of Indian origin, despite the high burden of MDR-TB in India. We enrolled adults and adolescents receiving cycloserine for MDR-TB at a tertiary hospital in Mumbai, India, in a prospective cohort. Total daily doses ranged from 500 to 750 mg, and participants underwent serial PK sampling on multiple visits starting 1 month after treatment initiation. PK data were analyzed using non-linear mixed-effect modeling. A total of 180 participants (117 f

SUBMITTER: Resendiz-Galvan JE 

PROVIDER: S-EPMC12486832 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature